Colleoni, Marco

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,827

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,276

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,025

Overall survival with ribociclib plus endocrine therapy in breast cancer

Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,001

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Piccart, M., Procter, M., Fumagalli, D., de Azambuja, E., Clark, E., Ewer, M. S., Restuccia, E., Jerusalem, G., Dent, S., Reaby, L., et al. (2021) · Journal of Clinical Oncology

HER2/EGFR in Cancer ResearchBreast Cancer Treatment Studies

Cited by 364

Depression and degree of acceptance of adjuvant cytotoxic drugs

Colleoni, M., Mandala, M., Peruzzotti, G., Robertson, C., Bredart, A., & Goldhirsch, A. (2000) · The Lancet

Cancer survivorship and carePatient-Provider Communication in Healthcare

Cited by 351

Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence

Chirgwin, J. H., Giobbie-Hurder, A., Coates, A. S., Price, K. N., Ejlertsen, B., Debled, M., Gelber, R. D., Goldhirsch, A., Smith, I., Rabaglio, M., et al. (2016) · Journal of Clinical Oncology

Breast Cancer Treatment StudiesMedication Adherence and Compliance

Cited by 244

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

Gnant, M., Dueck, A. C., Frantal, S., Martin, M., Burstein, H. J., Greil, R., Fox, P., Wolff, A. C., Chan, A., Winer, E. P., et al. (2022) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 235

Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

Cristofanilli, M., Rugo, H. S., Im, S.-A., Slamon, D. J., Harbeck, N., Bondarenko, I., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., et al. (2022) · Clinical Cancer Research

Advanced Breast Cancer TherapiesPARP inhibition in cancer therapy

Cited by 207

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L., et al. (2014) · Annals of Oncology

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 177

Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3.

Cristofanilli, M., Rugo, H. S., Im, S.-A., Slamon, D. J., Harbeck, N., Bondarenko, I., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., et al. (2021) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesPARP inhibition in cancer therapy

Cited by 65

Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib

Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S., Chow, L., Sohn, J., Lee, K. S., et al. (2021) · Cancer Research

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 30